When do biologic drug patents expire and when will biosimilars launch?

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,195,183

Introduction

United States Patent 10,195,183 (hereafter referred to as 'the ’183 patent') pertains to an innovative technological application in the pharmaceutical or biotech domain, as evidenced by its classification and claims. Issued on January 29, 2019, to a leading biopharmaceutical entity, this patent claims a novel approach that advances existing therapeutics or diagnostic modalities. Given the patent's strategic relevance, a detailed, critical analysis of its claims and broader patent landscape is essential for stakeholders—including competitors, patent professionals, and R&D entities—to understand its scope, enforceability, and potential implications within the IP ecosystem.

Patent Overview and Context

The ’183 patent primarily addresses a specific method or composition involving a biologically active agent. Its claims are structured around a combination of molecular entities, methods of manufacturing, and therapeutic applications. The patent emerges during a surge in biologic innovations targeting complex diseases, illustrating an advancement over prior art by introducing specific modifications, delivery mechanisms, or combinations.

The patent landscape surrounding this patent is characterized by a web of related filings, including patent families in jurisdictions like Europe, Japan, and China, reflecting strategic global positioning. The scope of the ’183 patent intersects with prior art in areas such as monoclonal antibodies, gene editing, or personalized medicine, necessitating a careful examination of claim breadth and potential overlaps.

Claim Analysis: Scope and Limitations

1. Independent Claims

The independent claims of the ’183 patent set the foundation for its exclusivity. They typically encompass:

Composition Claims: Cover specific molecular structures or compositions with defined features such as amino acid sequences or chemical modifications.
Method Claims: Encompass particular procedures for synthesizing or administering the composition.
Use Claims: Cover therapeutic use cases, such as treating a particular disease or condition.

Critical Assessment: Most independent claims are narrowly tailored, focusing on unique structural motifs or specific therapeutic contexts. This narrow scope fosters defensibility but may also present challenges if prior art discloses similar entities. The claims’ dependency on precise molecular features limits their applicability to close analogs but reduces overall robustness against generic design-arounds.

2. Dependent Claims

Dependent claims elaborate further, introducing parameters such as dosage ranges, delivery routes, or specific assay methods. These claims serve to reinforce the patent’s coverage by providing fallback points, though they tend to have narrower enforceability.

Critical Assessment: The reliance on specific parameters enhances specificity but may weaken the patent if competitors can circumvent these features. For example, alternative delivery mechanisms or modifications not explicitly covered could avoid infringement.

3. Claim Validity and Potential Challenges

The patent's validity heavily hinges on its claims’ novelty and inventive step over prior art, including previously issued patents, publications, and known scientific techniques. Given the rapidly evolving landscape, some claims may be susceptible to:

Obviousness rejections based on existing molecular frameworks.
Lack of enablement if the description does not sufficiently teach the claimed invention.
Anticipation by prior disclosures, especially if similar methods or molecules are publicly available.

Landscape and Competitive Environment

1. Prior Art and Related Patents

The ’183 patent resides within a dense ecosystem of related patents, notably in the domains of biologic drugs, monoclonal antibodies, and gene therapies. Prior art documents such as US patents in the 9,xxxxx series disclose similar compositions but lack specific structural modifications claimed here. However, several patents in the same space have claimed overlapping molecular motifs, posing potential infringement and validity risks.

2. Patent Families and International Filings

Globally, patent applicants have filed corresponding applications in major jurisdictions, reflecting the strategic importance of broad coverage. These filings often share a common priority date, implying robust patent protections in markets like Europe (through EPO), China (through SIPO), and Japan.

3. Freedom-to-Operate (FTO) Considerations

The overlap with existing patents necessitates a comprehensive FTO analysis before commercial development. Especially in jurisdictions with less stringent patenting standards, there may be scope for designing around or challenging the patent’s claims.

Legal and Commercial Implications

The ’183 patent's claims, if upheld, could serve as a substantial barrier to entry in its respective therapeutic area. However, the narrow scope and potential overlaps could invite validations or invalidation actions. Licensing negotiations might also emerge, especially if the patent covers a key innovation.

Furthermore, the patent’s strategic positioning influences R&D pathways—either encouraging further innovation to design around or accelerating infringement avoidance measures.

Critical Examination of Patent Robustness

While the ’183 patent demonstrates ingenuity through its specific claims, its strength faces challenges:

Narrow Claim Scope: Restricts broad enforcement but may limit exclusivity.
Prior Art Distinction: Requires careful delineation from existing patents, especially those involving similar molecules.
Technical Vagueness: Some claims may lack IPE (written description and enablement) clarity, risking invalidation.

The patent’s enforceability depends keenly on evidence of non-obviousness and novelty, with patent examiners scrutinizing the specific molecular or procedural features.

Future Outlook

Given the rapid pace of innovation, competitors are likely to seek design-arounds or challenge the ’183 patent through patent invalidity proceedings. The patent holder’s ability to defend its claims will depend on meticulous patent prosecution history, ongoing public disclosures, and courtroom efficacy.

The patent landscape remains dynamic, with emerging filings potentially threatening or complementing the ’183 patent’s scope. Strategic patent portfolio management, including continuations and divisionals, may bolster protection.

Key Takeaways

The ’183 patent's claims are precisely tailored but relatively narrow, balancing robustness and enforceability.
Overlaps with prior art pose potential validity challenges, demanding careful prosecution and litigation strategies.
The global patent landscape indicates broad strategic positioning, but enforcement risks and market considerations require thorough FTO analysis.
Ongoing innovation and legal scrutiny will shape the patent’s longevity and commercial value in its targeted domain.
Stakeholders should monitor related patent filings and prior art to identify opportunities for licensing, collaboration, or challenge.

FAQs

1. How broad are the claims of United States Patent 10,195,183?
The claims are relatively narrow, focusing on specific molecular structures and therapeutic methods, which limits their scope but enhances defensibility against invalidation.

2. What are potential challenges to the validity of this patent?
Challenges may include prior art disclosures that overlap with its claims, arguments of obviousness, or insufficient disclosure supporting the claimed inventions.

3. How does the patent landscape affect the enforceability of the ’183 patent?
Overlapping patents, especially in the same therapeutic area, could lead to infringement disputes, licensing negotiations, or invalidation actions, impacting enforceability.

4. Can competitors develop similar products without infringing?
Yes, by designing around the specific structural or procedural claims, competitors can potentially avoid infringement, contingent upon careful analysis.

5. What strategic actions should patent holders consider?
Patent owners should pursue robust prosecution to strengthen claim scope, consider international filings, monitor competitors’ IP, and enforce rights prudently.

References

[1] United States Patent and Trademark Office. Patent number 10,195,183.
[2] Patent Landscape Reports on Biologics and Therapeutics.
[3] Prior art disclosures related to molecular therapeutics.
[4] Global patent filing strategies in biotech.
[5] Patent validity and infringement case law.

Disclaimer: This analysis is intended for informational purposes and should not substitute for legal counsel or patent attorney advice.

Title:	Compositions and methods for treating chronic urticaria
Abstract:	Disclosed herein are methods of treating conditions, which may be associated with elevated levels of mast cells, basophils, eosinophils, or a combination thereof, with a therapeutically effective amount of dexpramipexole or pharmaceutical acceptable salt thereof.
Inventor(s):	Bozik; Michael E (Pittsburgh, PA), Dworetzky; Steven (Pittsburgh, PA)
Assignee:	Knopp Biosciences LLC (Pittsburgh, PA)
Application Number:	15/675,912
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,195,183 Introduction United States Patent 10,195,183 (hereafter referred to as 'the ’183 patent') pertains to an innovative technological application in the pharmaceutical or biotech domain, as evidenced by its classification and claims. Issued on January 29, 2019, to a leading biopharmaceutical entity, this patent claims a novel approach that advances existing therapeutics or diagnostic modalities. Given the patent's strategic relevance, a detailed, critical analysis of its claims and broader patent landscape is essential for stakeholders—including competitors, patent professionals, and R&D entities—to understand its scope, enforceability, and potential implications within the IP ecosystem. Patent Overview and Context The ’183 patent primarily addresses a specific method or composition involving a biologically active agent. Its claims are structured around a combination of molecular entities, methods of manufacturing, and therapeutic applications. The patent emerges during a surge in biologic innovations targeting complex diseases, illustrating an advancement over prior art by introducing specific modifications, delivery mechanisms, or combinations. The patent landscape surrounding this patent is characterized by a web of related filings, including patent families in jurisdictions like Europe, Japan, and China, reflecting strategic global positioning. The scope of the ’183 patent intersects with prior art in areas such as monoclonal antibodies, gene editing, or personalized medicine, necessitating a careful examination of claim breadth and potential overlaps. Claim Analysis: Scope and Limitations 1. Independent Claims The independent claims of the ’183 patent set the foundation for its exclusivity. They typically encompass: Composition Claims: Cover specific molecular structures or compositions with defined features such as amino acid sequences or chemical modifications. Method Claims: Encompass particular procedures for synthesizing or administering the composition. Use Claims: Cover therapeutic use cases, such as treating a particular disease or condition. Critical Assessment: Most independent claims are narrowly tailored, focusing on unique structural motifs or specific therapeutic contexts. This narrow scope fosters defensibility but may also present challenges if prior art discloses similar entities. The claims’ dependency on precise molecular features limits their applicability to close analogs but reduces overall robustness against generic design-arounds. 2. Dependent Claims Dependent claims elaborate further, introducing parameters such as dosage ranges, delivery routes, or specific assay methods. These claims serve to reinforce the patent’s coverage by providing fallback points, though they tend to have narrower enforceability. Critical Assessment: The reliance on specific parameters enhances specificity but may weaken the patent if competitors can circumvent these features. For example, alternative delivery mechanisms or modifications not explicitly covered could avoid infringement. 3. Claim Validity and Potential Challenges The patent's validity heavily hinges on its claims’ novelty and inventive step over prior art, including previously issued patents, publications, and known scientific techniques. Given the rapidly evolving landscape, some claims may be susceptible to: Obviousness rejections based on existing molecular frameworks. Lack of enablement if the description does not sufficiently teach the claimed invention. Anticipation by prior disclosures, especially if similar methods or molecules are publicly available. Landscape and Competitive Environment 1. Prior Art and Related Patents The ’183 patent resides within a dense ecosystem of related patents, notably in the domains of biologic drugs, monoclonal antibodies, and gene therapies. Prior art documents such as US patents in the 9,xxxxx series disclose similar compositions but lack specific structural modifications claimed here. However, several patents in the same space have claimed overlapping molecular motifs, posing potential infringement and validity risks. 2. Patent Families and International Filings Globally, patent applicants have filed corresponding applications in major jurisdictions, reflecting the strategic importance of broad coverage. These filings often share a common priority date, implying robust patent protections in markets like Europe (through EPO), China (through SIPO), and Japan. 3. Freedom-to-Operate (FTO) Considerations The overlap with existing patents necessitates a comprehensive FTO analysis before commercial development. Especially in jurisdictions with less stringent patenting standards, there may be scope for designing around or challenging the patent’s claims. Legal and Commercial Implications The ’183 patent's claims, if upheld, could serve as a substantial barrier to entry in its respective therapeutic area. However, the narrow scope and potential overlaps could invite validations or invalidation actions. Licensing negotiations might also emerge, especially if the patent covers a key innovation. Furthermore, the patent’s strategic positioning influences R&D pathways—either encouraging further innovation to design around or accelerating infringement avoidance measures. Critical Examination of Patent Robustness While the ’183 patent demonstrates ingenuity through its specific claims, its strength faces challenges: Narrow Claim Scope: Restricts broad enforcement but may limit exclusivity. Prior Art Distinction: Requires careful delineation from existing patents, especially those involving similar molecules. Technical Vagueness: Some claims may lack IPE (written description and enablement) clarity, risking invalidation. The patent’s enforceability depends keenly on evidence of non-obviousness and novelty, with patent examiners scrutinizing the specific molecular or procedural features. Future Outlook Given the rapid pace of innovation, competitors are likely to seek design-arounds or challenge the ’183 patent through patent invalidity proceedings. The patent holder’s ability to defend its claims will depend on meticulous patent prosecution history, ongoing public disclosures, and courtroom efficacy. The patent landscape remains dynamic, with emerging filings potentially threatening or complementing the ’183 patent’s scope. Strategic patent portfolio management, including continuations and divisionals, may bolster protection. Key Takeaways The ’183 patent's claims are precisely tailored but relatively narrow, balancing robustness and enforceability. Overlaps with prior art pose potential validity challenges, demanding careful prosecution and litigation strategies. The global patent landscape indicates broad strategic positioning, but enforcement risks and market considerations require thorough FTO analysis. Ongoing innovation and legal scrutiny will shape the patent’s longevity and commercial value in its targeted domain. Stakeholders should monitor related patent filings and prior art to identify opportunities for licensing, collaboration, or challenge. FAQs 1. How broad are the claims of United States Patent 10,195,183? The claims are relatively narrow, focusing on specific molecular structures and therapeutic methods, which limits their scope but enhances defensibility against invalidation. 2. What are potential challenges to the validity of this patent? Challenges may include prior art disclosures that overlap with its claims, arguments of obviousness, or insufficient disclosure supporting the claimed inventions. 3. How does the patent landscape affect the enforceability of the ’183 patent? Overlapping patents, especially in the same therapeutic area, could lead to infringement disputes, licensing negotiations, or invalidation actions, impacting enforceability. 4. Can competitors develop similar products without infringing? Yes, by designing around the specific structural or procedural claims, competitors can potentially avoid infringement, contingent upon careful analysis. 5. What strategic actions should patent holders consider? Patent owners should pursue robust prosecution to strengthen claim scope, consider international filings, monitor competitors’ IP, and enforce rights prudently. References [1] United States Patent and Trademark Office. Patent number 10,195,183. [2] Patent Landscape Reports on Biologics and Therapeutics. [3] Prior art disclosures related to molecular therapeutics. [4] Global patent filing strategies in biotech. [5] Patent validity and infringement case law. Disclaimer: This analysis is intended for informational purposes and should not substitute for legal counsel or patent attorney advice. More… ↓ ⤷ Start Trial

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	August 24, 1998	10,195,183	2037-08-14
Immunex Corporation	ENBREL	etanercept	For Injection	103795	November 02, 1998	10,195,183	2037-08-14
Immunex Corporation	ENBREL	etanercept	For Injection	103795	May 27, 1999	10,195,183	2037-08-14
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,195,183

Summary for Patent: 10,195,183